Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
about
PEGylation of Interferon-β-1aPeginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis CPeginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis CPegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis CPegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis CPEGylated Adenoviruses: From Mice to MonkeysNew developments in the treatment of hepatitis CManaging chronic hepatitis C in the difficult-to-treat patientA Single N-Acetylgalactosamine Residue at Threonine 106 Modifies the Dynamics and Structure of Interferon 2a around the Glycosylation SiteAnti-hepatitis C virus drugs and kidneyInfluence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patientsDiagnosis, management, and treatment of hepatitis C: an updateChronic hepatitis C treatment patterns in African American patients: an update.Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells.Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study.Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Combination immunotherapy for high-risk resected and metastatic melanoma patientsTreatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modelingPharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomesEffects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.Hepatitis C virus experimental model systems and antiviral drug research.Kinetic and dynamic computational model-based characterization of new proteins in mice: application to interferon alpha linked to apolipoprotein A-I.Identification of hepatitis C virus inhibitors targeting different aspects of infection using a cell-based assayNew therapeutic strategies for hepatitis C.Potential treatment options and future research to increase hepatitis C virus treatment response ratePharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.Protein-polymer conjugates: synthetic approaches by controlled radical polymerizations and interesting applications.Emerging synthetic approaches for protein-polymer conjugationsTreating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.A perspective on modelling hepatitis C virus infection.Investigational pharmacologic treatment for liver disease.Optimal therapy of hepatitis C.Side effects of therapy of hepatitis C and their management.Polyethylene glycol-interferon: current status in hepatitis C virus therapy.Essential thrombocythemia (ET): moving from palliation to cure.Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.Peginterferon-alpha2a (40 kDa) for chronic hepatitis C.Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients.Pegylation: engineering improved biopharmaceuticals for oncology.
P2860
Q22241420-9F6ACA37-B35E-4F56-A3E6-A07946C87ECFQ24200189-62896AE7-8AB0-4880-97EB-DB218802AA12Q24200197-D126D57C-1615-4F5B-8946-067600751B4CQ24240315-33FD7569-4BC6-45DF-8701-6727A692213CQ24241360-39B81828-CD28-45EA-BB75-5E6EE3A8E8B5Q24635276-6C661D75-DC5C-405F-9647-4D80400B8E3BQ27477964-5129CC67-66D4-4A7B-812A-7FBD2BD059E9Q27490409-1FB4DEDB-2422-4182-A2C6-FDB4143D2B91Q27675256-96385A28-7C10-4FEA-A5D4-DBED3C901B2DQ28070279-6AC6F9AB-BCC4-4C2A-AA25-9DD0DDBC557DQ28740552-93233548-2E76-453C-9433-8826413AED50Q29619682-A5E8C9F3-1B82-4F39-AE9D-744460C1B9EAQ33212476-A2FA49C7-95D8-4B1A-BA50-966873563381Q33364273-3615D858-65B7-4092-9628-88A93FAA62D8Q33370971-0D9A5779-5B20-47D9-8FAA-1AA3AABEDEB3Q33392904-D8BD5D08-2BC2-4754-8EF3-1FF0E4830EA9Q33559298-FE78A4C2-14BD-4833-8526-288D9F5F3A18Q33737498-F4EF9A9E-B739-414F-8C32-AE4E8944A89EQ33899320-2AEB9910-4AB5-43ED-82D3-A3FDD63ACC2DQ34208650-2E138795-69B6-444A-82BD-28B81200C842Q34225751-599D29FE-9B0E-49C0-A6DD-2F46992E7489Q34235286-B0D90076-B4BF-4A92-8448-B7BAD84CE059Q34359523-C984C8DA-ECFB-4EC5-B265-BB9D920335E8Q34403294-AB281D81-2367-4226-B8EB-F2BFF8BD5ACCQ34490190-04B705F1-8624-4840-B218-3C7A069282AAQ34576190-66DCE1BB-F381-418C-94D9-EFE6E19E64FEQ34594791-2639CBD5-DE2F-43AD-8E82-2F49DF0E5988Q34716081-68FD1AA1-018E-42FE-AB57-8FC05A5FC423Q34732445-FCE18E47-9F4E-412B-8EB9-5B7F0EEAA60FQ34747443-A320EB7B-2B27-4B76-A1BD-84BA4075F6A0Q34759489-17043C2B-B06E-4389-8136-5D21D051349DQ34841865-1B284253-18F8-4B84-A90F-8F867472777DQ34984079-FE7026E3-7F88-4201-BB1F-6F9AD0405616Q34984142-CC149B9F-F595-44C7-A33E-F2BAC6AB2FE6Q35020845-6C881180-0162-40F1-A4E1-AB4C4D3EB26DQ35022117-B9B010E1-FB81-429D-9B4C-456CA744195CQ35030123-610EC1E4-27D1-4434-BECB-0182967ECE08Q35095217-0F378CB9-49C9-4C96-BB88-F8A4A56E0EC1Q35182682-1A642570-9781-4B46-9167-45BA95653CC7Q35200818-D59A1E57-D339-42E9-82E2-172C94D8FBCB
P2860
Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pegylated interferon-alpha2b: ...... C Intervention Therapy Group.
@ast
Pegylated interferon-alpha2b: ...... C Intervention Therapy Group.
@en
type
label
Pegylated interferon-alpha2b: ...... C Intervention Therapy Group.
@ast
Pegylated interferon-alpha2b: ...... C Intervention Therapy Group.
@en
prefLabel
Pegylated interferon-alpha2b: ...... C Intervention Therapy Group.
@ast
Pegylated interferon-alpha2b: ...... C Intervention Therapy Group.
@en
P2093
P356
P1476
Pegylated interferon-alpha2b: ...... C Intervention Therapy Group.
@en
P2093
C Raffanel
R Rouzier-Panis
P304
P356
10.1067/MCP.2000.110973
P407
P50
P577
2000-11-01T00:00:00Z